Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays.
暂无分享,去创建一个
Spyro Mousses | Galen Hostetter | Lukas Bubendorf | Juha Kononen | G. Hostetter | O. Kallioniemi | M. Raffeld | J. Kononen | L. Bubendorf | S. Mousses | A. Elkahloun | P. Koivisto | U. Wagner | R. Cornelison | N. Willi | Mark Raffeld | N. Goldberger | Olli-P Kallioniemi | Pasi Koivisto | Niels Willi | Urs Wagner | Robert Cornelison | Natalie Goldberger | Abdel G Elkahloun | William Ferhle | Guito Sauter | G. Sauter | William Ferhle
[1] O. Kallioniemi,et al. Clinical and functional target validation using tissue and cell microarrays. , 2002, Current opinion in chemical biology.
[2] G. Makhatadze,et al. Oligomerization and divalent ion binding properties of the S100P protein: a Ca2+/Mg2+-switch model. , 1998, Journal of molecular biology.
[3] M. Resnick,et al. Xenografts of primary human prostatic carcinoma. , 1993, Journal of the National Cancer Institute.
[4] P. Kantoff,et al. Regulation of S100P expression by androgen , 1996, The Prostate.
[5] S. Schwartz,et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.
[6] G. Wistow,et al. mu-crystallin is a mammalian homologue of Agrobacterium ornithine cyclodeaminase and is expressed in human retina. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[7] E Mahlamäki,et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.
[8] O. Kallioniemi,et al. Tissue microarray technology for high-throughput molecular profiling of cancer. , 2001, Human molecular genetics.
[9] S. Dhanasekaran,et al. Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.
[10] W. V. van Weerden,et al. Use of nude mouse xenograft models in prostate cancer research , 2000, The Prostate.
[11] M. Kneba,et al. Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin‐resistant cell lines: comparison of mRNA differential display reverse transcription‐polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression , 1998, Anti-cancer drugs.
[12] Spyro Mousses,et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling , 2001, Oncogene.
[13] T. Pretlow,et al. CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy. , 1996, Journal of the National Cancer Institute.
[14] M. Ito,et al. mu-Crystallin, thyroid hormone-binding protein, is expressed abundantly in the murine inner root sheath cells. , 2000, The Journal of investigative dermatology.
[15] Y. Chen,et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. , 2000, Journal of the National Cancer Institute.
[16] J. Russo,et al. S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. , 2000, International journal of oncology.
[17] F. Peale,et al. Detection of novel gene expression in paraffin‐embedded tissues by isotopic in situ hybridization in tissue microarrays , 2001, The Journal of pathology.
[18] L. Sapinoso,et al. Functional dissection of transcriptional profiles in androgen-dependent and -independent prostate cancer , 2001, Nature Genetics.
[19] N. Carter,et al. Characterization of the Lmo4 gene encoding a LIM-only protein: genomic organization and comparative chromosomal mapping , 1999, Mammalian Genome.
[20] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[21] W. E. Gye,et al. CANCER RESEARCH , 1923, British medical journal.
[22] J. Isaacs,et al. The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.
[23] G. Makhatadze,et al. Cloning, overexpression, purification, and spectroscopic characterization of human S100P , 1998, Protein science : a publication of the Protein Society.
[24] Y. Saga,et al. Identification and characterization of LMO4, an LMO gene with a novel pattern of expression during embryogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[25] S. Schwartz,et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.